Master Alliance Provisions Guide (MAPGuide)

PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement

  • Business model | Governance

14. GENERAL PROVISIONS

[…]

14.12 The Parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated IC official, or designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available.